Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br />
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center (MSK), discusses the rationale for the phase II study of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (ccRCC).
Combinations of anti-VEGF and PD-1/PD-L1 inhibitors have shown great efficacy in clinical studies involving patients with kidney cancer. The question then became whether these combinations would still be effective in patients who previously progressed on a PD-1 inhibitor. Because of the speculation surrounding the idea of treating patients with another immune checkpoint inhibitor after they progressed on one, researchers at MSK decided to launch a study.
The results of the interim analysis, which included 33 patients from the study, showed partial responses in 64% of patients at 24 weeks of follow-up. The study also demonstrated a median progression-free survival of 11.2 months.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
